CF PHARMTECH (02652) Files with China Securities Regulatory Commission for Proposed H-Share Full Circulation

Stock News

01/12

CF PHARMTECH (02652) announced that on January 12, 2026, the company submitted a filing application to the China Securities Regulatory Commission concerning the proposed implementation of an H-share full circulation. The plan involves converting approximately 107.4 million domestic non-traded shares into H-shares on a one-for-one basis. Upon completion of all filing requirements, including the filing with the CSRC, and after obtaining all relevant approvals—such as the Hong Kong Stock Exchange's approval for the conversion and listing—while complying with all applicable laws, regulations, and rules, the approximately 107.4 million non-traded shares will be converted into 107.4 million H-shares. These shares will subsequently be listed and traded on the Hong Kong Stock Exchange.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1178261156"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1178261156\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1178261156?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-12 21:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1178261156","market":"fut","top_or_hot":-1,"title":"CF PHARMTECH (02652) Files with China Securities Regulatory Commission for Proposed H-Share Full Circulation","media":"Stock News","content":"<p>CF PHARMTECH (02652) announced that on January 12, 2026, the company submitted a filing application to the China Securities Regulatory Commission concerning the proposed implementation of an H-share full circulation. The plan involves converting approximately 107.4 million domestic non-traded shares into H-shares on a one-for-one basis. Upon completion of all filing requirements, including the filing with the CSRC, and after obtaining all relevant approvals—such as the Hong Kong Stock Exchange's approval for the conversion and listing—while complying with all applicable laws, regulations, and rules, the approximately 107.4 million non-traded shares will be converted into 107.4 million H-shares. These shares will subsequently be listed and traded on the Hong Kong Stock Exchange.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CF PHARMTECH (02652) Files with China Securities Regulatory Commission for Proposed H-Share Full Circulation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCF PHARMTECH (02652) Files with China Securities Regulatory Commission for Proposed H-Share Full Circulation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-01-12 21:28</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>CF PHARMTECH (02652) announced that on January 12, 2026, the company submitted a filing application to the China Securities Regulatory Commission concerning the proposed implementation of an H-share full circulation. The plan involves converting approximately 107.4 million domestic non-traded shares into H-shares on a one-for-one basis. Upon completion of all filing requirements, including the filing with the CSRC, and after obtaining all relevant approvals—such as the Hong Kong Stock Exchange's approval for the conversion and listing—while complying with all applicable laws, regulations, and rules, the approximately 107.4 million non-traded shares will be converted into 107.4 million H-shares. These shares will subsequently be listed and traded on the Hong Kong Stock Exchange.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02652","symbol_name":"長風藥業","start_time":0,"source_url":"","article_id":"1178261156","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1178261156","pubTimestamp":1768224499,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CF PHARMTECH (02652) announced that on January 12, 2026, the company submitted a filing application to the China Securities Regulatory Commission concerning the proposed implementation of an H-share...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02652":"长风药业"},"translate_title":"CF PHARMTECH(02652)向中国证监会提交建议H股全流通文件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02652":1},"content_text":"CF PHARMTECH (02652) announced that on January 12, 2026, the company submitted a filing application to the China Securities Regulatory Commission concerning the proposed implementation of an H-share full circulation. The plan involves converting approximately 107.4 million domestic non-traded shares into H-shares on a one-for-one basis. Upon completion of all filing requirements, including the filing with the CSRC, and after obtaining all relevant approvals—such as the Hong Kong Stock Exchange's approval for the conversion and listing—while complying with all applicable laws, regulations, and rules, the approximately 107.4 million non-traded shares will be converted into 107.4 million H-shares. These shares will subsequently be listed and traded on the Hong Kong Stock Exchange.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}